“And as we look ahead to our fiscal fourth quarter, we expect our revenue and EPS growth to accelerate as we build on momentum in important growth markets and continue to drive earnings leverage.”

In context

“h in cardiac ablation solutions powered by our PFA portfolio. Leadless pacing, neuromodulation, and diabetes all grew double-digits. And structural heart excluding congenital and U.S. cranial and spinal technologies both grew high-single-digits. We advanced our innovation pipeline and are opening up the largest total addressable market in MedTech with renal denervation. It's an exciting time as we're stacking growth drivers on top of growth drivers with groundbreaking innovation in some of the most attractive markets in MedTech. We overcame a short-term U.S. distributor dynamic and delivered strong earnings power with high-single-digit EPS growth coming in ahead of both consensus and the high end of our guidance range with strong improvements in both our gross margin and operating margin. And as we look ahead to our fiscal fourth quarter, we expect our revenue and EPS growth to accelerate as we build on momentum in important growth markets and continue to drive earnings leverage. We expect our formula of delivering durable revenue growth, leveraged earnings, and generating strong free cash flow to create significant value for our shareholders. Now let's turn to the details of our Q3 business results and discuss our performance. Starting first with our cardiovascular portfolio, which grew mid-single-digits overall. The highlight was our Cardiac Ablation Solutions business. Now we forecasted strong double-digit growth this quarter and CAS delivered meaningful acceleration, growing 22%. Our Pulse Field Ablation products are driving rapid growth. We've hit a new gear on supply, and demand for our PFA portfolio continues to accelerate. We are the only company with two PFA platforms, Affera and PulseSelect, which gives us flexibility. Affera has separated itself from th”